Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats
The result is a patchwork of coverage policies across all 50 states
For this reason, it is essential to continue developing additional treatments that target different biological pathways
Fill out a health history questionnaire and consult with an online physician
Place the pen in the main compartment, not the freezer
From its initial use in the treatment of type 2 diabetes to its expansion to 12 indications such as obesity, cardiovascular disease, chronic kidney disease, and metabolic dysfunction related fatty liver disease (MASLD), the annual sales of GLP-1 drugs exceeded 100 billion dollars, and its research and development funding reached a historical peak of 21.72 million dollars in 2025